Breast Cancer Testing Available Summer 2009
MammaPrint, Oncotype DX, and Breast Bioclassifier
Patient/Tumor Characteristics MammaPrint® Oncotype DX™ Bioclassifier™
ER+
ER-
Node+
Node-
Stage I and II
Stage III–IV
Over 61 years old
Test Characteristics MammaPrint® Oncotype DX™ Bioclassifier™
Formalin-fixed embedded tissue
Sample processed in United States
qRT-PCR
Prognostic
References:
1 van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;
347:1999-2009.
2 Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med
2004; 351:2817-26.
3 Parker J, Mullins M, Cheang M, Davies S, Mardis E, Nielsen TO, Ellis MJ, Marron S, Perou CM, Bernard PS. A supervised risk predictor of
breast cancer based on biological subtypes. 08-AB-31340-ASCOAM.
University Genomics, Inc.
ARUP LABORATORIES